Symbols / KLRS $8.81 +1.61%
KLRS Chart
About
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 164.77M |
| Enterprise Value | 89.31M | Income | -55.47M | Sales | — |
| Book/sh | 2.24 | Cash/sh | 4.12 | Dividend Yield | — |
| Payout | 0.00% | Employees | 14 | IPO | — |
| P/E | — | Forward P/E | -3.70 | PEG | — |
| P/S | — | P/B | 3.94 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 12.70 |
| Current Ratio | 12.89 | Debt/Eq | 3.69 | LT Debt/Eq | — |
| EPS (ttm) | -38.05 | EPS next Y | -2.38 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-12 08:00 | ROA | -63.50% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 18.70M |
| Shs Float | 1.83M | Short Float | 18.94% | Short Ratio | 14.58 |
| Short Interest | — | 52W High | 12.90 | 52W Low | 2.14 |
| Beta | — | Avg Volume | 81.92K | Volume | 84.68K |
| Target Price | $19.83 | Recom | Strong_buy | Prev Close | $8.67 |
| Price | $8.81 | Change | 1.61% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$19.83
Mean price target
2. Current target
$8.57
Latest analyst target
3. DCF / Fair value
$-12.34
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.57
Low
$5.00
High
$26.00
Mean
$19.83
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-23 | init | Chardan Capital | — → Buy | $19 |
| 2025-11-03 | init | Citizens | — → Market Outperform | $20 |
| 2025-09-03 | init | Raymond James | — → Strong Buy | $23 |
| 2025-04-08 | init | William Blair | — → Outperform | — |
- Retinal drug developer Kalaris posts $43M loss, funded into late 2027 - Stock Titan ue, 17 Mar 2026 12
- Kalaris (Nasdaq: KLRS) trims 2025 loss as $118M cash funds TH103 trials - Stock Titan ue, 17 Mar 2026 12
- Kalaris Therapeutics (NASDAQ:KLRS) Raised to "Hold" at Wall Street Zen - MarketBeat Sun, 15 Mar 2026 05
- Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates - marketscreener.com ue, 17 Mar 2026 12
- Insider Stock Purchases: February 18, 2026 - Quiver Quantitative Wed, 18 Feb 2026 08
- William Blair reiterates Kalaris stock rating on TH103 potential - Investing.com Mon, 09 Mar 2026 20
- Kalaris Therapeutics, Inc.'s (NASDAQ:KLRS) biggest owners are private equity firms who got richer after stock soared 24% last week - Yahoo Finance Sun, 28 Sep 2025 07
- Kalaris Updates TH103 Strategy and Highlights Cash Runway - TipRanks Mon, 09 Mar 2026 11
- Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts (KLRS) - Seeking Alpha Fri, 19 Dec 2025 08
- Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know - Nasdaq Mon, 01 Sep 2025 07
- Private equity firms in Kalaris Therapeutics, Inc. (NASDAQ:KLRS) are its biggest bettors, and their bets paid off as stock gained 24% last week - simplywall.st Sun, 28 Sep 2025 07
- Kalaris Therapeutics (NASDAQ:KLRS) Rating Lowered to Sell at Wall Street Zen - MarketBeat Sat, 07 Mar 2026 09
- We Think Kalaris Therapeutics (NASDAQ:KLRS) Needs To Drive Business Growth Carefully - Yahoo Finance hu, 27 Nov 2025 08
- Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth (KLRS) - Seeking Alpha hu, 18 Dec 2025 08
- Kalaris Therapeutics (KLRS) Price Target Increased by 10.87% to 17.34 - Nasdaq Mon, 17 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1500000 | 15000000.0 | — | Stock Award(Grant) at price 10.00 per share. | AKKARAJU SRINIVAS | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-22 00:00:00 | I |
| 1 | 479847 | 5000006.0 | — | Purchase at price 10.42 per share. | AKKARAJU SRINIVAS | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-18 00:00:00 | I |
| 2 | 907 | 8135.0 | — | Sale at price 8.97 per share. | HAGEN BRETT R. | Officer | — | 2025-03-26 00:00:00 | D |
| 3 | 352800 | — | — | Stock Award(Grant) at price 0.00 per share. | PATEL SAMIRBHAI CHANDRAKANTH M.D. | Director | — | 2025-03-18 00:00:00 | D/I |
| 4 | 4030 | — | — | Stock Award(Grant) at price 0.00 per share. | FEINSOD MATTHEW | Officer | — | 2025-03-18 00:00:00 | D |
| 5 | 504000 | — | — | Stock Award(Grant) at price 0.00 per share. | FERRARA NAPOLEONE | Director | — | 2025-03-18 00:00:00 | D |
| 6 | 11444503 | — | — | Stock Award(Grant) at price 0.00 per share. | AKKARAJU SRINIVAS | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-03-18 00:00:00 | I |
| 7 | 106 | 1068.0 | — | Sale at price 10.08 per share. | MILLER EDWARD | General Counsel | — | 2025-02-21 00:00:00 | D |
| 8 | 96 | 967.0 | — | Sale at price 10.08 per share. | HAGEN BRETT R. | Officer | — | 2025-02-21 00:00:00 | D |
| 9 | 303 | 3053.0 | — | Sale at price 10.08 per share. | SINHA VIKAS | Chief Executive Officer | — | 2025-02-21 00:00:00 | D |
Financials
| Line Item | 2023-12-31 | 2022-12-31 |
|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 |
| NormalizedEBITDA | -14.32M | -15.79M |
| TotalUnusualItems | 307.00K | 543.00K |
| TotalUnusualItemsExcludingGoodwill | 307.00K | 543.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -14.70M | -15.48M |
| EBITDA | -14.01M | -15.25M |
| EBIT | -14.01M | -15.25M |
| NetInterestIncome | -687.00K | -235.00K |
| InterestExpense | 687.00K | 235.00K |
| NormalizedIncome | -15.01M | -16.03M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -14.70M | -15.48M |
| TotalExpenses | 13.46M | 14.01M |
| TotalOperatingIncomeAsReported | -13.46M | -14.01M |
| DilutedAverageShares | 1.33M | 1.33M |
| BasicAverageShares | 1.33M | 1.33M |
| DilutedEPS | -11.05 | -11.64 |
| BasicEPS | -11.05 | -11.64 |
| DilutedNIAvailtoComStockholders | -14.70M | -15.48M |
| NetIncomeCommonStockholders | -14.70M | -15.48M |
| NetIncome | -14.70M | -15.48M |
| NetIncomeIncludingNoncontrollingInterests | -14.70M | -15.48M |
| NetIncomeContinuousOperations | -14.70M | -15.48M |
| PretaxIncome | -14.70M | -15.48M |
| OtherIncomeExpense | -548.00K | -1.24M |
| OtherNonOperatingIncomeExpenses | -855.00K | -1.79M |
| GainOnSaleOfSecurity | 307.00K | 543.00K |
| NetNonOperatingInterestIncomeExpense | -687.00K | -235.00K |
| InterestExpenseNonOperating | 687.00K | 235.00K |
| OperatingIncome | -13.46M | -14.01M |
| OperatingExpense | 13.46M | 14.01M |
| ResearchAndDevelopment | 11.71M | 11.76M |
| SellingGeneralAndAdministration | 1.76M | 2.24M |
| GeneralAndAdministrativeExpense | 1.76M | 2.24M |
| OtherGandA | 1.76M | 2.24M |
| TotalRevenue | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 |
| Line Item | 2023-12-31 | 2022-12-31 |
|---|---|---|
| OrdinarySharesNumber | 18.70M | 18.70M |
| ShareIssued | 18.70M | 18.70M |
| NetDebt | 194.00K | |
| TotalDebt | 3.25M | |
| TangibleBookValue | -45.02M | -30.27M |
| InvestedCapital | -45.02M | -27.02M |
| WorkingCapital | -609.00K | -1.79M |
| NetTangibleAssets | -45.02M | -30.27M |
| CommonStockEquity | -45.02M | -30.27M |
| TotalCapitalization | -45.02M | -27.02M |
| TotalEquityGrossMinorityInterest | -45.02M | -30.27M |
| StockholdersEquity | -45.02M | -30.27M |
| RetainedEarnings | -47.39M | -32.70M |
| AdditionalPaidInCapital | 2.38M | 2.42M |
| CapitalStock | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 48.35M | 34.17M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 44.41M | 28.48M |
| PreferredSecuritiesOutsideStockEquity | 44.41M | 24.96M |
| DerivativeProductLiabilities | 0.00 | 262.00K |
| LongTermDebtAndCapitalLeaseObligation | 3.25M | |
| LongTermDebt | 3.25M | |
| CurrentLiabilities | 3.94M | 5.69M |
| OtherCurrentLiabilities | 74.00K | 38.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 466.00K | 258.00K |
| PayablesAndAccruedExpenses | 3.40M | 5.39M |
| CurrentAccruedExpenses | 1.03M | 2.62M |
| Payables | 2.38M | 2.78M |
| DuetoRelatedPartiesCurrent | 13.00K | 21.00K |
| AccountsPayable | 2.36M | 2.76M |
| TotalAssets | 3.33M | 3.90M |
| TotalNonCurrentAssets | 0.00 | 0.00 |
| CurrentAssets | 3.33M | 3.90M |
| OtherCurrentAssets | 17.00K | 3.00K |
| PrepaidAssets | 147.00K | 837.00K |
| CashCashEquivalentsAndShortTermInvestments | 3.17M | 3.06M |
| CashAndCashEquivalents | 3.17M | 3.06M |
| Line Item | 2023-12-31 | 2022-12-31 |
|---|---|---|
| FreeCashFlow | -14.13M | -9.78M |
| IssuanceOfDebt | 6.00M | 4.30M |
| IssuanceOfCapitalStock | 6.74M | 8.47M |
| EndCashPosition | 3.17M | 3.06M |
| BeginningCashPosition | 3.06M | 58.00K |
| ChangesInCash | 110.00K | 3.00M |
| FinancingCashFlow | 14.24M | 12.78M |
| CashFlowFromContinuingFinancingActivities | 14.24M | 12.78M |
| NetOtherFinancingCharges | 1.50M | |
| ProceedsFromStockOptionExercised | 0.00 | 5.00K |
| NetPreferredStockIssuance | 6.74M | 8.47M |
| PreferredStockIssuance | 6.74M | 8.47M |
| NetIssuancePaymentsOfDebt | 6.00M | 4.30M |
| NetLongTermDebtIssuance | 6.00M | 4.30M |
| LongTermDebtIssuance | 6.00M | 4.30M |
| OperatingCashFlow | -14.13M | -9.78M |
| CashFlowFromContinuingOperatingActivities | -14.13M | -9.78M |
| ChangeInWorkingCapital | -1.09M | 3.40M |
| ChangeInPayablesAndAccruedExpense | -1.77M | 3.98M |
| ChangeInAccruedExpense | -1.37M | 2.15M |
| ChangeInPayable | -402.00K | 1.83M |
| ChangeInAccountPayable | -402.00K | 1.83M |
| ChangeInPrepaidAssets | 676.00K | -582.00K |
| OtherNonCashItems | 1.82M | 2.58M |
| StockBasedCompensation | 148.00K | 271.00K |
| OperatingGainsLosses | -307.00K | -543.00K |
| GainLossOnInvestmentSecurities | -307.00K | -543.00K |
| NetIncomeFromContinuingOperations | -14.70M | -15.48M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for KLRS
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|